$MAIA News

MAIA Biotechnology Receives FDA IND Clearance To Expand THIO-101 Phase 2 NSCLC Trial In U.S. With Ateganosine; Updates Manufacturing Protocols Supporting Potential Accelerated Approval Pathway

MAIA Biotechnology Insiders Founder/CEO Vlad Vitoc, M.D. And Director Stan V. Smith, Ph.D. Increase Ownership Position Through Open Market Purchases Of ~147,700 Shares Worth ~$201K

MAIA Biotechnology Announces That It Delivered A Poster Presentation Featuring The Methodology And Study Design For Its Pivotal Phase 3 Clinical Trial On May 31 At The 2026 Annual Meeting Of The American Society Of Clinical Oncology

Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)

MAIA Biotechnology Q1 EPS $(0.14) Beats $(0.18) Estimate

MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer

MAIA Biotechnology Activates First Clinical Facility In U.S. In Its Phase 2 THIO-101 Expansion Study To Treat Non-Small Cell Lung Cancer

MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy

MAIA Biotechnology Expects $33M In Proceeds From Public Offering To Fully Fund Phase 3 Clinical Trial For Non-Small Cell Lung Cancer Treatment Ateganosine

MAIA Biotechnology Expects $33M In Proceeds From Public Offering To Fully Fund Phase 3 Clinical Trial For Non-Small Cell Lung Cancer Treatment Ateganosine

MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer

MAIA Biotechnology Reports Over 2-Year Survival In Phase 2 THIO-101 NSCLC Trial;

MAIA Biotechnology Q4 EPS $(0.08) Beats $(0.13) Estimate

Is the Market Bullish or Bearish on MAIA Biotechnology Inc?

MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock

On March 2, 2026, MAIA Biotechnology Entered Into An Underwriting Agreement With Konik Capital Partners; To Issue 20,000,000 Shares Of Common Stock In Public Offering

Reported Earlier, MAIA Biotechnology Raises $30M Through 20M Common Share Public Offering At $1.50 Per Share To Fund Cancer Immunotherapy Clinical Trials

MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock

MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

MAIA Biotechnology Reveals Proposed Underwritten Public Offering of Common Stock And Pre-Funded Warrants; No Size Disclosed